세계의 제산제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2030년)

The global demand for Antacids Market is presumed to reach the market size of nearly USD 10.68 BN by 2030 from USD 7.68 BN in 2022 with a CAGR of 4.21% under the study period 2023 - 2030.

Antacids are medicines used to relieve or prevent symptoms associated with excessive stomach acids, such as heartburn, indigestion, acid reflux, and stomach ulcers. These medication work by neutralizing the acid in the stomach, which helps to reduce the discomfort and burning sensation caused by the excess acid.

MARKET DYNAMICS:

Gastrointestinal disorders such as GERD, peptic ulcers, and dyspepsia are becoming increasingly prevalent, leading to a higher need for antacids. These conditions result in excessive stomach acid production and symptoms like heartburn and acid reflux, creating a demand for these drugs to alleviate discomfort. Modern lifestyles, including irregular eating patterns, consumption of spicy and fatty foods, and high levels of stress, contribute to increased gastric acid production and the need for these medicines. The growing global geriatric population, who are more prone to gastrointestinal disorders, is a significant consumer group for antacids. The market demand for gastrointestinal disorders is driven by increased consumer awareness of these conditions and the availability of over-the-counter medicines, leading to a preference for self-medication. Stress, sedentary lifestyles, and certain occupations also contribute to gastrointestinal symptoms and the need for antacids. The overall increase in healthcare expenditure and accessibility to healthcare services has resulted in more individuals seeking medical advice and treatment for gastrointestinal symptoms. Healthcare professionals often recommend it as an initial option for managing mild to moderate symptoms, further driving the demand.

The research covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of antacids. The growth and trends of antacids industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the antacids market provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Dosage Form

• Tablet
• Liquid
• Others

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Antacids market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the antacids market include GlaxoSmithKline plc, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy's Laboratories Ltd., Sanofi, Reckitt Benckiser Group plc, Sun Pharmaceuticals Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc., Procter & Gamble. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . ANTACIDS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Dosage Form
  • 3.7.2 Market Attractiveness Analysis By Distribution Channel
  • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ANTACIDS MARKET ANALYSIS BY DOSAGE FORM

• 5.1 Overview by Dosage Form
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Dosage Form
• 5.4 Tablet Historic and Forecast Sales by Regions
• 5.5 Liquid Historic and Forecast Sales by Regions
• 5.6 Others Historic and Forecast Sales by Regions

6 . GLOBAL ANTACIDS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 6.1 Overview by Distribution Channel
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Distribution Channel
• 6.4 Retail Pharmacy Historic and Forecast Sales by Regions
• 6.5 Hospital Pharmacy Historic and Forecast Sales by Regions
• 6.6 Online Pharmacy Historic and Forecast Sales by Regions

7 . GLOBAL ANTACIDS MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE ANTACIDS COMPANIES

• 8.1. Antacids Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF ANTACIDS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. GlaxoSmithKline plc
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Bayer AG
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. Boehringer Ingelheim International GmbH
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. Dr. Reddy's Laboratories Ltd.
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. Sanofi
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. Reckitt Benckiser Group plc
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Sun Pharmaceuticals Ltd.
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. Takeda Pharmaceutical Company Limited
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments
• 9.11. Pfizer Inc.
  • 9.11.1. Company Overview
  • 9.11.2. Company Revenue
  • 9.11.3. Products
  • 9.11.4. Recent Developments
• 9.12. Procter & Gamble
  • 9.12.1. Company Overview
  • 9.12.2. Company Revenue
  • 9.12.3. Products
  • 9.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies